|
Organon & Co. (OGN) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Organon & Co. (OGN) Bundle
Gain insights into your Organon & Co. (OGN) valuation analysis using our state-of-the-art DCF Calculator! This Excel template is preloaded with real (OGN) data, enabling you to adjust forecasts and assumptions for a precise calculation of Organon & Co.'s intrinsic value.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,096.0 | 6,304.0 | 6,174.0 | 6,263.0 | 6,403.0 | 6,074.5 | 5,762.9 | 5,467.3 | 5,186.8 | 4,920.7 |
| Revenue Growth, % | 0.00 | -22.13 | -2.06 | 1.44 | 2.24 | -5.13 | -5.13 | -5.13 | -5.13 | -5.13 |
| EBITDA | 2,989.0 | 1,814.0 | 1,690.0 | 1,436.0 | 1,604.0 | 1,713.6 | 1,625.7 | 1,542.3 | 1,463.2 | 1,388.1 |
| EBITDA, % | 36.92 | 28.78 | 27.37 | 22.93 | 25.05 | 28.21 | 28.21 | 28.21 | 28.21 | 28.21 |
| Depreciation | 142.0 | 195.0 | 212.0 | 236.0 | 277.0 | 199.2 | 189.0 | 179.3 | 170.1 | 161.4 |
| Depreciation, % | 1.75 | 3.09 | 3.43 | 3.77 | 4.33 | 3.28 | 3.28 | 3.28 | 3.28 | 3.28 |
| EBIT | 2,847.0 | 1,619.0 | 1,478.0 | 1,200.0 | 1,327.0 | 1,514.4 | 1,436.7 | 1,363.0 | 1,293.1 | 1,226.7 |
| EBIT, % | 35.17 | 25.68 | 23.94 | 19.16 | 20.72 | 24.93 | 24.93 | 24.93 | 24.93 | 24.93 |
| Total Cash | 500.0 | 737.0 | 706.0 | 693.0 | 675.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,090.0 | 1,382.0 | 1,475.0 | 1,744.0 | 1,358.0 | 1,316.3 | 1,248.8 | 1,184.8 | 1,124.0 | 1,066.3 |
| Account Receivables, % | 13.46 | 21.92 | 23.89 | 27.85 | 21.21 | 21.67 | 21.67 | 21.67 | 21.67 | 21.67 |
| Inventories | 913.0 | 915.0 | 1,003.0 | 1,315.0 | 1,321.0 | 1,016.3 | 964.1 | 914.7 | 867.8 | 823.2 |
| Inventories, % | 11.28 | 14.51 | 16.25 | 21.00 | 20.63 | 16.73 | 16.73 | 16.73 | 16.73 | 16.73 |
| Accounts Payable | 259.0 | 1,382.0 | 1,132.0 | 1,314.0 | 1,153.0 | 1,001.7 | 950.3 | 901.6 | 855.3 | 811.4 |
| Accounts Payable, % | 3.20 | 21.92 | 18.33 | 20.98 | 18.01 | 16.49 | 16.49 | 16.49 | 16.49 | 16.49 |
| Capital Expenditure | -278.0 | -488.0 | -427.0 | -261.0 | -175.0 | -303.7 | -288.1 | -273.4 | -259.3 | -246.0 |
| Capital Expenditure, % | -3.43 | -7.74 | -6.92 | -4.17 | -2.73 | -5.00 | -5.00 | -5.00 | -5.00 | -5.00 |
| Tax Rate, % | 19.40 | 11.64 | 18.27 | -52.01 | -7.06 | -1.95 | -1.95 | -1.95 | -1.95 | -1.95 |
| EBITAT | 2,294.6 | 1,430.5 | 1,208.0 | 1,824.1 | 1,420.7 | 1,543.9 | 1,464.7 | 1,389.6 | 1,318.3 | 1,250.7 |
| Depreciation | 142.0 | 195.0 | 212.0 | 236.0 | 277.0 | 199.2 | 189.0 | 179.3 | 170.1 | 161.4 |
| Changes in Account Receivables | 41.7 | 67.5 | 64.0 | 60.8 | 57.7 | |||||
| Changes in Inventories | 304.7 | 52.2 | 49.4 | 46.9 | 44.6 | |||||
| Changes in Accounts Payable | -151.3 | -51.4 | -48.7 | -46.3 | -43.9 | |||||
| Capital Expenditure | -278.0 | -488.0 | -427.0 | -261.0 | -175.0 | -303.7 | -288.1 | -273.4 | -259.3 | -246.0 |
| UFCF | 414.6 | 1,966.5 | 562.0 | 1,400.1 | 1,741.7 | 1,634.5 | 1,433.8 | 1,360.3 | 1,290.5 | 1,224.4 |
| WACC, % | 5.35 | 5.68 | 5.40 | 6.19 | 6.19 | 5.76 | 5.76 | 5.76 | 5.76 | 5.76 |
| PV UFCF | 1,545.5 | 1,281.9 | 1,149.9 | 1,031.5 | 925.4 | |||||
| SUM PV UFCF | 5,934.2 | |||||||||
| Long Term Growth Rate, % | 0.50 | |||||||||
| Free cash flow (T + 1) | 1,230.5 | |||||||||
| Terminal Value | 23,394.0 | |||||||||
| Present Terminal Value | 17,680.6 | |||||||||
| Enterprise Value | 23,614.8 | |||||||||
| Net Debt | 8,205.0 | |||||||||
| Equity Value | 15,409.8 | |||||||||
| Diluted Shares Outstanding, MM | 259.0 | |||||||||
| Equity Value Per Share | 59.50 |
What You Will Get
- Real Organon Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Organon & Co. (OGN).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Organon & Co. (OGN).
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Organon & Co.'s (OGN) fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Organon & Co. (OGN).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for Organon & Co. (OGN).
Key Features
- 🔍 Real-Life OGN Financials: Pre-filled historical and projected data for Organon & Co. (OGN).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Organon’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Organon’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Organon & Co.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions regarding Organon & Co. (OGN).
Why Choose This Calculator for Organon & Co. (OGN)?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses all in one solution.
- Customizable Inputs: Modify the yellow-highlighted cells to explore different scenarios.
- Detailed Insights: Automatically determines Organon & Co.'s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points.
- Professional Quality: Perfect for financial analysts, investors, and business consultants.
Who Should Use Organon & Co. (OGN)?
- Healthcare Investors: Make informed investment choices with reliable insights into the pharmaceutical sector.
- Market Analysts: Streamline your research with comprehensive data and analysis tools specific to Organon & Co. (OGN).
- Consultants: Efficiently tailor reports and presentations for clients focusing on women's health and biosimilars.
- Pharmaceutical Enthusiasts: Enhance your knowledge of healthcare innovations and market trends surrounding Organon & Co. (OGN).
- Students and Educators: Utilize it as a valuable resource in healthcare management and business courses.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Organon & Co. (OGN) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Organon & Co. (OGN).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.